Fate Therapeutics Inc

NASDAQ:FATE  
76.56
+0.01 (+0.01%)
Products, Earnings Announcements

Fate Therapeutics Reports Positive Interim Data From Its Phase 1 Study Of Ft516 In Combination With Rituximab For B-Cell Lymphoma

Published: 12/04/2020 21:09 GMT
Fate Therapeutics Inc (FATE) - Fate Therapeutics Reports Positive Interim Data From Its Phase 1 Study of Ft516 in Combination With Rituximab for B-cell Lymphoma.
Fate Therapeutics Inc - 3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response.
Fate Therapeutics Inc - Six Doses of Ft516 Were Well-tolerated With No Ft516-related Grade 3 Or Greater Adverse Events Reported by Investigators.
Fate Therapeutics Inc - No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-associated Neurotoxicity Syndrome.
Revenue is expected to be $6.6 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $6.64 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.